10% Off $75 Orders! Use Code SAVE10P Shop Now
One use per customer. Not available with Autoship. Expires 5/28/18.

Complement split products C3a and C4a are early markers of acute lyme disease in tick bite patients in the United States.

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...

Abstract

BACKGROUND:

Current laboratory markers do not readily detect acute
Lyme disease. We assessed the utility of complement and its split products as markers of
Lyme disease in patients shortly after a tick bite.

METHODS:

Thirty-one consecutive acute
Lyme disease patients, 14 with and 17 without erythema migrans (EM) skin rash, seen by a physician within 96 h of a tick bite were matched with 24 consecutive tick bite patients without
Lyme disease symptoms and 46 healthy control subjects. Complement and split products measured included factor B, Bb, C4, C3c, C3a(des Arg), C4a(des Arg), C1q- and C3d-containing immune complexes, and C2.

RESULTS:

C2, C4, C3 and factor B levels were within normal ranges in all groups. C3a and C4a levels were significantly higher in acute
Lyme disease patients than in tick bite and healthy control groups (both p < 0.001). All acute
Lyme disease patients, regardless of EM, had elevated levels of C3a or C4a. Few tick bite controls had elevated levels of C3a (2/20) or C4a (5/24) and only 1 of the healthy control subjects had elevated C3a (0/46) or C4a (1/32).

CONCLUSIONS:

These findings suggest that C3a and C4a may be useful markers of
Lyme disease in patients seen shortly after tick bite, even in those without EM.

(c) 2008 S. Karger AG, Basel

Int Arch Allergy Immunol. 2008;146(3):255-61. doi: 10.1159/000116362. Epub 2008 Feb 13.

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...



Leave a Reply